Who founded Revitope Oncology?

Revitope Oncology was founded by Andrew Allen in 2016.

How much funding has Revitope Oncology raised?

Revitope Oncology has disclosed $8.2M raised across 1 round.

Where is Revitope Oncology headquartered?

Revitope Oncology is headquartered in San Francisco, US.

Revitope Oncology

San Francisco, US · Founded 2016 · Delaware corporation

Revitope Oncology is a biotechnology company developing precision cancer immunotherapies using its TwoGATE T cell engager platform, which uses paired tumor-targeted bispecific antibodies that become active only on cancer cells co-expressing two antigens to limit toxicity to healthy tissue. Its pipeline focuses on solid tumor indications, developed in-house and through partnerships with companies such as Genmab and Junshi Biosciences.

Biotech Deep Tech Healthtech

Founders & leadership

Revitope Oncology was founded in 2016 by Andrew Allen.

Andrew AllenChairman & Founder

Julie CherringtonExecutive

Steve ArkinstallChief Executive Officer

Werner MeierChief Scientific Officer

Mark ClementChief Operating Officer

Mark CobboldNamed on SEC filing

Board

Raj MehtaBoard director

Peter JoostBoard director

Reported raises · per SEC filings

Form D private placements

$8.2M disclosed across 1 round · 2016

▶$8.2MraisedSep 2016 · 12 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Mark CobboldDirector
Julie CherringtonExecutive Officer, Director
Raj MehtaDirector
Peter JoostDirector
Andrew AllenExecutive Officer, Director

Offering amount: $8.2M
Amount sold: $8.2M
First sale: Feb 2016
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Solu13 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Kyverna Therapeutics12 shared keywordsKyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.

Companies competing with Revitope Oncology for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Revitope Oncology do?: Revitope Oncology is a biotechnology company developing precision cancer immunotherapies using its TwoGATE T cell engager platform, which uses paired tumor-targeted bispecific antibodies that become active only on cancer cells co-expressing two antigens to limit toxicity to healthy tissue. Its pipeline focuses on solid tumor indications, developed in-house and through partnerships with companies such as Genmab and Junshi Biosciences.
Who founded Revitope Oncology?: Revitope Oncology was founded by Andrew Allen in 2016.
How much funding has Revitope Oncology raised?: Revitope Oncology has disclosed $8.2M raised across 1 round.
Where is Revitope Oncology headquartered?: Revitope Oncology is headquartered in San Francisco, US.